OBJECTIVE: To investigate the impact and timing of smoking cessation on developing rheumatoid arthritis (RA) and serologic phenotypes. METHODS: We investigated smoking cessation and RA risk in the Nurses' Health Study (NHS) (1976-2014) and the NHS II (1989-2015). Smoking exposures and covariates were obtained by biennial questionnaires. Self-reported RA was confirmed by medical record review for American College of Rheumatology/European League Against Rheumatism criteria. Cox regression was used to estimate hazard ratios (HRs) and 95% confidence intervals (95% CIs) for RA serologic phenotypes (all, seropositive, seronegative) according to smoking status, intensity, pack-years, and years since cessation. RESULTS: Among 230,732 women, we identified 1,528 incident cases of RA (63.4% of which were seropositive) during 6,037,151 person-years of follow-up. Compared with never smoking, current smoking increased the risk of all RA (multivariable HR 1.47, 95% CI 1.27-1.72) and seropositive RA (HR 1.67, 95% CI 1.38-2.01) but not seronegative RA (HR 1.20, 95% CI 0.93-1.55). An increasing number of smoking pack-years was associated with an increased trend for the risk of all RA (P < 0.0001) and seropositive RA (P < 0.0001). With increasing duration of smoking cessation, a decreased trend for the risk of all RA was observed (P = 0.009) and seropositive RA (P = 0.002). Compared to recent quitters (<5 years), those who quit ≥30 years ago had an HR of 0.63 (95% CI 0.44-0.90) for seropositive RA. However, a modestly increased risk of RA was still detectable 30 years after quitting smoking (for all RA, HR 1.25 [95% CI 1.02-1.53]; for seropositive RA, HR 1.30 [95% CI 1.01-1.68]; reference, never smoking). CONCLUSION: These results confirm that smoking is a strong risk factor for developing seropositive RA and demonstrate for the first time that a behavior change of sustained smoking cessation could delay or even prevent seropositive RA.
OBJECTIVE: To investigate the impact and timing of smoking cessation on developing rheumatoid arthritis (RA) and serologic phenotypes. METHODS: We investigated smoking cessation and RA risk in the Nurses' Health Study (NHS) (1976-2014) and the NHS II (1989-2015). Smoking exposures and covariates were obtained by biennial questionnaires. Self-reported RA was confirmed by medical record review for American College of Rheumatology/European League Against Rheumatism criteria. Cox regression was used to estimate hazard ratios (HRs) and 95% confidence intervals (95% CIs) for RA serologic phenotypes (all, seropositive, seronegative) according to smoking status, intensity, pack-years, and years since cessation. RESULTS: Among 230,732 women, we identified 1,528 incident cases of RA (63.4% of which were seropositive) during 6,037,151 person-years of follow-up. Compared with never smoking, current smoking increased the risk of all RA (multivariable HR 1.47, 95% CI 1.27-1.72) and seropositive RA (HR 1.67, 95% CI 1.38-2.01) but not seronegative RA (HR 1.20, 95% CI 0.93-1.55). An increasing number of smoking pack-years was associated with an increased trend for the risk of all RA (P < 0.0001) and seropositive RA (P < 0.0001). With increasing duration of smoking cessation, a decreased trend for the risk of all RA was observed (P = 0.009) and seropositive RA (P = 0.002). Compared to recent quitters (<5 years), those who quit ≥30 years ago had an HR of 0.63 (95% CI 0.44-0.90) for seropositive RA. However, a modestly increased risk of RA was still detectable 30 years after quitting smoking (for all RA, HR 1.25 [95% CI 1.02-1.53]; for seropositive RA, HR 1.30 [95% CI 1.01-1.68]; reference, never smoking). CONCLUSION: These results confirm that smoking is a strong risk factor for developing seropositive RA and demonstrate for the first time that a behavior change of sustained smoking cessation could delay or even prevent seropositive RA.
Authors: F B Hu; E Rimm; S A Smith-Warner; D Feskanich; M J Stampfer; A Ascherio; L Sampson; W C Willett Journal: Am J Clin Nutr Date: 1999-02 Impact factor: 7.045
Authors: Henrik Källberg; Bo Ding; Leonid Padyukov; Camilla Bengtsson; Johan Rönnelid; Lars Klareskog; Lars Alfredsson Journal: Ann Rheum Dis Date: 2010-12-13 Impact factor: 19.103
Authors: D Makrygiannakis; M Hermansson; A-K Ulfgren; A P Nicholas; A J W Zendman; A Eklund; J Grunewald; C M Skold; L Klareskog; A I Catrina Journal: Ann Rheum Dis Date: 2008-04-15 Impact factor: 19.103
Authors: Kathleen Chang; So Min Yang; Seong Heon Kim; Kyoung Hee Han; Se Jin Park; Jae Il Shin Journal: Int J Mol Sci Date: 2014-12-03 Impact factor: 5.923
Authors: H Maura Friedlander; Julia A Ford; Alessandra Zaccardelli; Alexsandra V Terrio; Michael H Cho; Jeffrey A Sparks Journal: Expert Rev Clin Immunol Date: 2020-01-06 Impact factor: 4.473
Authors: Kazuki Yoshida; Tzu-Chieh Lin; Melissa Y Wei; Susan Malspeis; Su H Chu; Carlos A Camargo; Benjamin A Raby; Hyon K Choi; Sara K Tedeschi; Medha Barbhaiya; Bing Lu; Karen H Costenbader; Elizabeth W Karlson; Jeffrey A Sparks Journal: Arthritis Care Res (Hoboken) Date: 2021-02 Impact factor: 4.794
Authors: Maria Schletzbaum; Xing Wang; Robert Greenlee; Megan E Piper; Christie M Bartels Journal: Arthritis Care Res (Hoboken) Date: 2021-05 Impact factor: 4.794
Authors: Sicong Huang; Vanessa L Kronzer; Paul F Dellaripa; Kevin D Deane; Marcy B Bolster; Vivek Nagaraja; Dinesh Khanna; Tracy J Doyle; Jeffrey A Sparks Journal: Curr Treatm Opt Rheumatol Date: 2020-09-01
Authors: Jeffrey A Sparks; Susan Malspeis; Jill Hahn; Jiaqi Wang; Andrea L Roberts; Laura D Kubzansky; Karen H Costenbader Journal: Arthritis Care Res (Hoboken) Date: 2021-01 Impact factor: 4.794
Authors: May Y Choi; Jill Hahn; Susan Malspeis; Emma F Stevens; Elizabeth W Karlson; Jeffrey A Sparks; Kazuki Yoshida; Laura Kubzansky; Karen H Costenbader Journal: Arthritis Rheumatol Date: 2022-01-11 Impact factor: 10.995